Show simple item record

dc.creatorStamatogiannis, N.en
dc.creatorMakris, D.en
dc.creatorZakynthinos, E.en
dc.date.accessioned2015-11-23T10:48:32Z
dc.date.available2015-11-23T10:48:32Z
dc.date.issued2009
dc.identifier10.2174/187221309789257469
dc.identifier.issn1872213X
dc.identifier.urihttp://hdl.handle.net/11615/33356
dc.description.abstractStatins, beyond their lipid lowering properties, have pleiotropic properties that may modulate the inflammatory cascade and potentially could be useful in the management of inflammatory conditions such as bacteremia and sepsis. In this article, we aimed to review significant patents and available evidence regarding the anti-inflammatory characteristics of these agents and their role in the clinical outcome of inflammatory conditions. Several studies have demonstrated beneficial effects of prior use of statins in the development and the progression of bacteremia, sepsis and pneumonia and there is evidence supporting that the use of statins may be associated with a decreased hospital mortality caused by the above disorders. These investigations also suggest that these agents are infrequently associated with adverse events and are generally safe and well tolerated. However, it should be underlined that these data come mainly from observational retrospective investigations and randomized prospective studies are warranted to confirm these encouraging results. © 2009 Bentham Science Publishers Ltd.en
dc.sourceRecent Patents on Inflammation and Allergy Drug Discoveryen
dc.source.urihttp://www.scopus.com/inward/record.url?eid=2-s2.0-70350784300&partnerID=40&md5=0d70f6c280f8a7013b44ea3e8247d381
dc.subjectPneumoniaen
dc.subjectSepsisen
dc.subjectSeptic shocken
dc.subjectStatinsen
dc.subject2,4 thiazolidinedione derivativeen
dc.subjectcholesterolen
dc.subjectendothelial nitric oxide synthaseen
dc.subjectheme oxygenaseen
dc.subjecthydroxymethylglutaryl coenzyme A reductaseen
dc.subjecthydroxymethylglutaryl coenzyme A reductase inhibitoren
dc.subjectinducible nitric oxide synthaseen
dc.subjectmevalonic aciden
dc.subjectmevinolinen
dc.subjectplaceboen
dc.subjectsimvastatinen
dc.subjectantiinflammatory activityen
dc.subjectbacteremiaen
dc.subjectcholesterol blood levelen
dc.subjectchronic obstructive lung diseaseen
dc.subjectclinical trialen
dc.subjectcommunity acquired pneumoniaen
dc.subjectcomorbidityen
dc.subjectcytokine productionen
dc.subjectdisease courseen
dc.subjectdose responseen
dc.subjectdrug efficacyen
dc.subjectdrug mechanismen
dc.subjectdrug protein bindingen
dc.subjectdrug safetyen
dc.subjectdrug tolerabilityen
dc.subjectdrug useen
dc.subjectenzyme activityen
dc.subjectenzyme inhibitionen
dc.subjectGram negative bacteriumen
dc.subjecthumanen
dc.subjectimmune responseen
dc.subjectimmunomodulationen
dc.subjectinflammationen
dc.subjectinfluenzaen
dc.subjectliver dysfunctionen
dc.subjectliver functionen
dc.subjectlow drug doseen
dc.subjectmortalityen
dc.subjectmyalgiaen
dc.subjectmyopathyen
dc.subjectmyositisen
dc.subjectoxidative stressen
dc.subjectpleiotropyen
dc.subjectpriority journalen
dc.subjectreviewen
dc.subjectrhabdomyolysisen
dc.subjectrisk assessmenten
dc.subjectrisk reductionen
dc.subjectside effecten
dc.subjectStaphylococcus aureusen
dc.subjectthorax radiographyen
dc.subjecttreatment outcomeen
dc.subjectvagus nerve stimulationen
dc.subjectAnti-Inflammatory Agentsen
dc.subjectClinical Trials as Topicen
dc.subjectHumansen
dc.subjectHydroxymethylglutaryl-CoA Reductase Inhibitorsen
dc.subjectPatents as Topicen
dc.titleStatins in bacteremia, sepsis and pneumonia: Have we found the holy grail?en
dc.typejournalArticleen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record